Caliber Imaging & Diagnostics, Inc. (LCDX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Caliber Imaging & Diagnostics, Inc. (LCDX). Caliber Imaging & Diagnostics, Inc. specializes in developing and marketing advanced imaging solutions for real-time cellular-level tissue visualization. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Caliber Imaging & Diagnostics, Inc. (LCDX) Healthcare & Pipeline Overview
Caliber Imaging & Diagnostics, Inc. focuses on innovative imaging technologies, providing cellular-level visualization tools like VivaScope for dermatology and research. With a small team and a focus on the U.S. market, the company aims to improve diagnostic accuracy and patient care through advanced imaging solutions in the medical devices sector.
Investment Thesis
Caliber Imaging & Diagnostics, Inc. presents a focused investment opportunity within the medical devices sector, centered on its VivaScope technology. The company's ability to provide real-time, cellular-level tissue imaging offers a potential advantage in dermatology and research applications. However, with a negative profit margin of -199.0% and negative free cash flow, the company's financial sustainability is a key concern. The company's small market capitalization and OTC listing introduce additional risk factors. The company's beta of 0.31 suggests lower volatility compared to the broader market. Investors should carefully consider the company's financial performance, market position, and growth prospects before making investment decisions.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Gross margin of 15.5% reflects the company's ability to generate revenue from its products, although it is relatively low compared to industry averages.
- Profit margin of -199.0% signifies substantial losses, highlighting the need for improved cost management and revenue generation.
- Free cash flow of $-0.00B indicates the company is not generating positive cash flow, requiring external funding or improved operational efficiency.
- Beta of 0.31 suggests the stock is less volatile than the market, potentially offering some stability during market fluctuations.
Competitors & Peers
Strengths
- Proprietary VivaScope technology.
- Real-time cellular-level imaging capabilities.
- Established presence in dermatology imaging.
- Potential for expansion into new therapeutic areas.
Weaknesses
- Negative profit margin and free cash flow.
- Small market capitalization.
- OTC listing introduces additional risk.
- Limited geographic reach.
Catalysts
- Ongoing: Expansion into new therapeutic areas, such as oncology or wound care, could drive revenue growth.
- Ongoing: Strategic partnerships with healthcare providers and research institutions could accelerate adoption of the VivaScope technology.
- Upcoming: Potential regulatory approvals or reimbursement changes could positively impact the company's market access.
- Ongoing: Development of new VivaScope models with enhanced capabilities could attract new customers and increase sales.
- Ongoing: Increased focus on digital telepathology solutions can drive recurring revenue and expand the company's reach.
Risks
- Ongoing: Negative profit margin and free cash flow raise concerns about the company's financial sustainability.
- Potential: Competition from established medical device companies could limit market share gains.
- Potential: Regulatory hurdles and reimbursement challenges could delay or prevent market access.
- Potential: Technological obsolescence could render the VivaScope technology less competitive.
- Ongoing: OTC listing introduces additional risk factors, including limited financial disclosure and low trading volume.
Growth Opportunities
- Expansion into new therapeutic areas represents a significant growth opportunity for Caliber Imaging & Diagnostics, Inc. While currently focused on dermatology, the VivaScope technology could be adapted for use in other medical specialties, such as oncology or wound care. The market for advanced imaging in these areas is substantial, offering the potential for increased revenue and market share. Success in this area depends on the company's ability to develop and validate new applications for its technology.
- Geographic expansion beyond the United States offers another avenue for growth. The demand for advanced imaging technologies is increasing globally, particularly in emerging markets with growing healthcare infrastructure. Caliber Imaging & Diagnostics, Inc. could explore partnerships or direct sales initiatives to enter new markets and expand its customer base. International expansion requires careful consideration of regulatory requirements and market dynamics.
- Development of new VivaScope models with enhanced capabilities could drive growth. The company could invest in research and development to create next-generation imaging systems with improved resolution, speed, or functionality. These advancements could attract new customers and increase sales to existing customers. Innovation is crucial for maintaining a competitive edge in the rapidly evolving medical device industry.
- Strategic partnerships with healthcare providers and research institutions could accelerate adoption of the VivaScope technology. By collaborating with key opinion leaders and early adopters, Caliber Imaging & Diagnostics, Inc. can increase awareness and generate clinical evidence to support the use of its products. Partnerships can also provide access to new markets and funding opportunities.
- Increased focus on digital telepathology solutions, such as VivaNet, can drive recurring revenue and expand the company's reach. Telepathology enables remote consultation and collaboration, which is particularly valuable in underserved areas or during public health emergencies. By offering a comprehensive telepathology platform, Caliber Imaging & Diagnostics, Inc. can generate subscription-based revenue and strengthen its relationships with healthcare providers.
Opportunities
- Expansion into new therapeutic areas (oncology, wound care).
- Geographic expansion beyond the United States.
- Development of new VivaScope models with enhanced capabilities.
- Strategic partnerships with healthcare providers and research institutions.
Threats
- Competition from established medical device companies.
- Regulatory hurdles and reimbursement challenges.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Proprietary VivaScope technology offering real-time cellular-level imaging.
- Established presence in the dermatology imaging market.
- Potential for network effects as more clinicians adopt the VivaScope technology.
- Intellectual property protection through patents and trademarks.
About LCDX
Founded in 1991 and headquartered in Andover, Massachusetts, Caliber Imaging & Diagnostics, Inc., formerly known as Lucid, Inc., designs, develops, and markets advanced imaging solutions. The company's core technology enables clinicians and researchers to visualize tissue at the cellular level in real-time. Their flagship product, the VivaScope 1500, is a reflectance confocal imaging system that captures high-resolution images of living tissue, aiding in the diagnosis and monitoring of skin conditions. The VivaScope 3000, a handheld version, offers greater flexibility for skin imaging. Caliber Imaging & Diagnostics also provides VivaScan software, which facilitates patient scheduling, image acquisition, review, and reporting. VivaNet, their digital telepathology system, enables remote consultation and collaboration among healthcare professionals. The company primarily serves the United States market, focusing on dermatology clinics, research institutions, and hospitals. Caliber Imaging & Diagnostics aims to enhance diagnostic accuracy, reduce invasive procedures, and improve patient outcomes through its innovative imaging technologies.
What They Do
- Designs and develops advanced imaging solutions for medical applications.
- Markets VivaScope 1500, a reflectance confocal imaging system.
- Offers VivaScope 3000, a handheld in vivo reflectance confocal microscope.
- Provides VivaScan software for patient scheduling, image acquisition, and reporting.
- Offers VivaNet, a digital telepathology system for remote consultation.
- Enables clinicians and researchers to visualize tissue at the cellular level in real-time.
Business Model
- Sales of VivaScope imaging systems to dermatology clinics, research institutions, and hospitals.
- Software licensing fees for VivaScan and VivaNet.
- Service and maintenance contracts for imaging systems.
- Potential for future revenue from consumables or disposables used with the imaging systems.
Industry Context
Caliber Imaging & Diagnostics, Inc. operates in the medical devices industry, which is characterized by technological innovation and regulatory scrutiny. The market for advanced imaging technologies is growing, driven by the increasing demand for non-invasive diagnostic procedures and personalized medicine. Competition includes established medical device companies and emerging players with novel imaging solutions. Caliber Imaging & Diagnostics aims to differentiate itself through its VivaScope technology, offering real-time cellular-level imaging for dermatology and research applications. The company's success depends on its ability to gain market share and achieve profitability in a competitive landscape.
Key Customers
- Dermatology clinics and practitioners.
- Research institutions and universities.
- Hospitals and medical centers.
- Pathologists and dermatopathologists.
Financials
Chart & Info
Caliber Imaging & Diagnostics, Inc. (LCDX) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LCDX.
Price Targets
Wall Street price target analysis for LCDX.
MoonshotScore
What does this score mean?
The MoonshotScore rates LCDX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: L. Michael Hone
CEO
L. Michael Hone serves as the CEO of Caliber Imaging & Diagnostics, Inc. His background includes extensive experience in managing and leading technology-driven companies. He has a proven track record in strategic planning, business development, and operational execution. Prior to joining Caliber Imaging & Diagnostics, Inc., Mr. Hone held leadership positions in various healthcare and technology firms, where he focused on driving innovation and growth. His expertise spans across product development, marketing, and sales, making him well-suited to lead Caliber Imaging & Diagnostics, Inc. in its mission to advance medical imaging technologies.
Track Record: Under L. Michael Hone's leadership, Caliber Imaging & Diagnostics, Inc. has focused on refining its VivaScope technology and expanding its market presence in the dermatology sector. He has overseen the development of new product features and enhancements, as well as strategic partnerships to drive adoption of the company's imaging solutions. His tenure has been marked by a commitment to innovation and customer satisfaction, although the company continues to face financial challenges.
LCDX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Caliber Imaging & Diagnostics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and transparency compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in LCDX.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- OTC Other tier status indicates a higher degree of risk compared to stocks listed on major exchanges.
- Potential for delisting or trading suspension due to non-compliance with OTC market regulations.
- Lack of analyst coverage and institutional interest can limit investor awareness and liquidity.
- Verify the company's financial statements and SEC filings (if available).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established presence in the dermatology imaging market.
- Proprietary VivaScope technology.
- Focus on innovation and customer satisfaction.
- Experienced management team.
- Potential for growth in the medical devices sector.
What Investors Ask About Caliber Imaging & Diagnostics, Inc. (LCDX)
What does Caliber Imaging & Diagnostics, Inc. do?
Caliber Imaging & Diagnostics, Inc. is a medical technology company that designs, develops, and markets advanced imaging solutions. Their primary product is the VivaScope, a confocal imaging system that allows clinicians and researchers to visualize tissue at the cellular level in real-time. This technology is primarily used in dermatology for non-invasive skin imaging and diagnostics. The company also offers software solutions like VivaScan and VivaNet to support image acquisition, analysis, and remote consultation. Caliber Imaging & Diagnostics, Inc. aims to improve diagnostic accuracy and patient outcomes through its innovative imaging technologies.
What do analysts say about LCDX stock?
As of 2026-03-16, there is limited analyst coverage for LCDX due to its OTC listing and small market capitalization. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are difficult to assess given the company's negative profit margin and limited financial disclosure. Growth considerations include the potential for expansion into new therapeutic areas and geographic markets, as well as the risks associated with competition and regulatory hurdles. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions.
What are the main risks for LCDX?
The main risks for Caliber Imaging & Diagnostics, Inc. include its negative profit margin and free cash flow, which raise concerns about its financial sustainability. The company also faces competition from established medical device companies and regulatory hurdles that could delay or prevent market access. Additionally, the OTC listing introduces additional risk factors, including limited financial disclosure and low trading volume. Technological obsolescence is another potential risk, as advancements in imaging technologies could render the VivaScope technology less competitive. Investors should carefully consider these risks before investing in LCDX.
What are the key factors to evaluate for LCDX?
Evaluating LCDX involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Proprietary VivaScope technology.. Primary risk to monitor: Ongoing: Negative profit margin and free cash flow raise concerns about the company's financial sustainability.. This is not financial advice.
How frequently does LCDX data refresh on this page?
LCDX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LCDX's recent stock price performance?
Recent price movement in Caliber Imaging & Diagnostics, Inc. (LCDX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary VivaScope technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LCDX overvalued or undervalued right now?
Determining whether Caliber Imaging & Diagnostics, Inc. (LCDX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LCDX?
Before investing in Caliber Imaging & Diagnostics, Inc. (LCDX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available due to OTC listing.
- AI analysis pending for LCDX.